142 related articles for article (PubMed ID: 20040648)
1. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - followup report.
Malaviya AN; Kapoor S; Garg S; Rawat R
J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040648
[No Abstract] [Full Text] [Related]
2. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
3. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries?
Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M
J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567
[No Abstract] [Full Text] [Related]
4. Tuberculosis associated with therapy against tumor necrosis factor alpha.
Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
[No Abstract] [Full Text] [Related]
5. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
7. Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.
Keane J; Ní Cheallaigh C
J Rheumatol; 2008 Jul; 35(7):1238-9. PubMed ID: 18597413
[No Abstract] [Full Text] [Related]
8. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
[TBL] [Abstract][Full Text] [Related]
9. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
10. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
Mariette X
Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
[No Abstract] [Full Text] [Related]
11. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience.
Pratt A; Nicholl K; Kay L
Rheumatology (Oxford); 2007 Jun; 46(6):1035-6. PubMed ID: 17409126
[No Abstract] [Full Text] [Related]
12. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
14. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
15. Detection of tuberculosis by extensive screening in a patient with rheumatoid arthritis prior to anti-TNF-alpha therapy.
Iseli A; Hüllstrung HD; Rodenhausen S; Widmer AF; Tyndall A; Hasler P
Rheumatology (Oxford); 2006 Aug; 45(8):1049-50. PubMed ID: 16769772
[No Abstract] [Full Text] [Related]
16. Comment on prescribing tumor necrosis factor inhibitors.
Hanauer LB
Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
[No Abstract] [Full Text] [Related]
17. Infection and anti-tumor necrosis factor-alpha therapy.
Zandman-Goddard G
Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
[No Abstract] [Full Text] [Related]
18. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
[TBL] [Abstract][Full Text] [Related]
19. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
[TBL] [Abstract][Full Text] [Related]
20. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
[Next] [New Search]